NeoVax

**NeoVax** is an investigational, patient-specific therapeutic cancer vaccine developed by Dana-Farber Cancer Institute. Each individualized preparation is designed from tumor and normal-tissue sequencing to identify somatic mutations and incorporates up to approximately 20 synthetic long peptides encoding selected tumor neoantigens, generally administered with the immune adjuvant poly-ICLC and, in some protocols, Montanide. The vaccine is intended to prime and expand neoantigen-reactive CD4-positive and CD8-positive T-cell responses, promoting recognition and killing of tumor cells while sparing normal tissues that lack the relevant mutation-derived antigens. NeoVax has been evaluated in early-stage studies across melanoma, glioblastoma, renal cell carcinoma, ovarian cancer, follicular lymphoma, and chronic lymphocytic leukemia, including combinations with immune-checkpoint inhibitors.

Brand names

NEO-PV-01NEO-PV01NEO-PV 01

Other names

Personalized neoantigen cancer vaccinePersonalized neoantigen peptide vaccine